摘要
Objective: To test the hypothesis that usage of foundation makeup (FM) and sunscreen lotion (SS), used individually or in combination, is associated with significant changes in the likelihood of lupus symptom exacerbation. Methods: Self-reported flare days (SRF) and use of FM and SS products, were retrospectively examined in 80 Caucasian Australian women with ACR classified SLE for a year. Negative binomial regression modelled SRF days (outcome) against independent FMSS variable and covariates: age;diagnosis years;outdoor hours;BMI;stress;immune therapy medication (ITM) use. Results: Statistically significant inverse associations between SRF days and FMSS use were found. Protective effects were statistically significant (p < 0.05) for combined FMSS exposure days (OR 0.998, CI 0.997 - 1.0) and FM alone (OR 0.603, CI 0.363 - 1.0). Significant associations consistent with increased SRF risk were seen in sub-analysis models for participants taking ITM: univariate model (OR 1.968, p = 0.03);multivariate model for FMSS (OR 2.11, CI 1.161 - 3.835);FM days (OR 1.855, CI 1.023 - 3.364). Results show SRF day reduction of 0.15% for each day of product exposure. Conclusion: Study results highlight protective effects of wearing FM with or without SS. This reduction in flare days ultimately has potential to improve quality of life in SLE patients.
Objective: To test the hypothesis that usage of foundation makeup (FM) and sunscreen lotion (SS), used individually or in combination, is associated with significant changes in the likelihood of lupus symptom exacerbation. Methods: Self-reported flare days (SRF) and use of FM and SS products, were retrospectively examined in 80 Caucasian Australian women with ACR classified SLE for a year. Negative binomial regression modelled SRF days (outcome) against independent FMSS variable and covariates: age;diagnosis years;outdoor hours;BMI;stress;immune therapy medication (ITM) use. Results: Statistically significant inverse associations between SRF days and FMSS use were found. Protective effects were statistically significant (p < 0.05) for combined FMSS exposure days (OR 0.998, CI 0.997 - 1.0) and FM alone (OR 0.603, CI 0.363 - 1.0). Significant associations consistent with increased SRF risk were seen in sub-analysis models for participants taking ITM: univariate model (OR 1.968, p = 0.03);multivariate model for FMSS (OR 2.11, CI 1.161 - 3.835);FM days (OR 1.855, CI 1.023 - 3.364). Results show SRF day reduction of 0.15% for each day of product exposure. Conclusion: Study results highlight protective effects of wearing FM with or without SS. This reduction in flare days ultimately has potential to improve quality of life in SLE patients.
